Metagenomi Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $25.2M | $52.3M | $44.8M | — |
| Research and development | $94.4M | $109.2M | $94.4M | — |
| Operating expenses | $121.2M | $141.2M | $123.2M | — |
| Operating income | -$96.0M | -$88.9M | -$78.5M | — |
| Pretax income | -$87.9M | -$83.6M | -$60.2M | — |
| Income tax expense | -$58,000 | -$5.5M | $8.0M | — |
| Net income | -$87.9M | -$78.1M | -$68.3M | — |
| Balance Sheet | ||||
| Cash and equivalents | $41.7M | $27.4M | $140.6M | — |
| Current assets | $165.5M | $258.0M | $278.3M | — |
| Total assets | $221.1M | $324.6M | $364.8M | — |
| Current liabilities | $22.9M | $37.3M | $68.9M | — |
| Total liabilities | $62.5M | $89.7M | $149.7M | — |
| Stockholders' equity | $158.6M | $234.9M | -$135.6M | -$74.4M |
| Cash Flow Statement | ||||
| Cash from operations | -$88.9M | -$109.1M | -$91.4M | — |
| Depreciation and amortization | $5.3M | $5.4M | $4.2M | — |
| Stock-based compensation | $11.9M | $16.2M | $6.9M | — |
| Capital expenditure | $574,000 | $3.1M | $9.8M | — |
| Free cash flow | -$89.5M | -$112.2M | -$101.2M | — |
| Impairments | — | $1.0M | $23,000 | — |
Shares outstanding 37.6M · Free float 66.5%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.